Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating restated by Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, January 10th.

60 Degrees Pharmaceuticals Price Performance

60 Degrees Pharmaceuticals stock opened at $0.83 on Friday. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $11.01. The firm has a market capitalization of $1.90 million, a price-to-earnings ratio of -0.08 and a beta of 4.40. The company’s 50 day simple moving average is $1.19 and its 200 day simple moving average is $1.02.

Insider Buying and Selling at 60 Degrees Pharmaceuticals

In other news, CEO Geoffrey S. Dow bought 35,823 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average price of $1.27 per share, with a total value of $45,495.21. Following the transaction, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. This represents a 60.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have purchased 66,372 shares of company stock valued at $82,410. 10.27% of the stock is currently owned by corporate insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.